Frequent inactivation of A20 in B-cell lymphomas - PubMed (original) (raw)
. 2009 Jun 4;459(7247):712-6.
doi: 10.1038/nature07969. Epub 2009 May 3.
Masashi Sanada, Itaru Kato, Yasuharu Sato, Junko Takita, Kengo Takeuchi, Akira Niwa, Yuyan Chen, Kumi Nakazaki, Junko Nomoto, Yoshitaka Asakura, Satsuki Muto, Azusa Tamura, Mitsuru Iio, Yoshiki Akatsuka, Yasuhide Hayashi, Hiraku Mori, Takashi Igarashi, Mineo Kurokawa, Shigeru Chiba, Shigeo Mori, Yuichi Ishikawa, Koji Okamoto, Kensei Tobinai, Hitoshi Nakagama, Tatsutoshi Nakahata, Tadashi Yoshino, Yukio Kobayashi, Seishi Ogawa
Affiliations
- PMID: 19412163
- DOI: 10.1038/nature07969
Frequent inactivation of A20 in B-cell lymphomas
Motohiro Kato et al. Nature. 2009.
Abstract
A20 is a negative regulator of the NF-kappaB pathway and was initially identified as being rapidly induced after tumour-necrosis factor-alpha stimulation. It has a pivotal role in regulation of the immune response and prevents excessive activation of NF-kappaB in response to a variety of external stimuli; recent genetic studies have disclosed putative associations of polymorphic A20 (also called TNFAIP3) alleles with autoimmune disease risk. However, the involvement of A20 in the development of human cancers is unknown. Here we show, using a genome-wide analysis of genetic lesions in 238 B-cell lymphomas, that A20 is a common genetic target in B-lineage lymphomas. A20 is frequently inactivated by somatic mutations and/or deletions in mucosa-associated tissue lymphoma (18 out of 87; 21.8%) and Hodgkin's lymphoma of nodular sclerosis histology (5 out of 15; 33.3%), and, to a lesser extent, in other B-lineage lymphomas. When re-expressed in a lymphoma-derived cell line with no functional A20 alleles, wild-type A20, but not mutant A20, resulted in suppression of cell growth and induction of apoptosis, accompanied by downregulation of NF-kappaB activation. The A20-deficient cells stably generated tumours in immunodeficient mice, whereas the tumorigenicity was effectively suppressed by re-expression of A20. In A20-deficient cells, suppression of both cell growth and NF-kappaB activity due to re-expression of A20 depended, at least partly, on cell-surface-receptor signalling, including the tumour-necrosis factor receptor. Considering the physiological function of A20 in the negative modulation of NF-kappaB activation induced by multiple upstream stimuli, our findings indicate that uncontrolled signalling of NF-kappaB caused by loss of A20 function is involved in the pathogenesis of subsets of B-lineage lymphomas.
Similar articles
- A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
Ando M, Sato Y, Takata K, Nomoto J, Nakamura S, Ohshima K, Takeuchi T, Orita Y, Kobayashi Y, Yoshino T. Ando M, et al. PLoS One. 2013;8(2):e56741. doi: 10.1371/journal.pone.0056741. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418597 Free PMC article. - TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, Stanelle J, Siebert R, Küppers R. Schmitz R, et al. J Exp Med. 2009 May 11;206(5):981-9. doi: 10.1084/jem.20090528. Epub 2009 Apr 20. J Exp Med. 2009. PMID: 19380639 Free PMC article. - TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M. Honma K, et al. Blood. 2009 Sep 17;114(12):2467-75. doi: 10.1182/blood-2008-12-194852. Epub 2009 Jul 16. Blood. 2009. PMID: 19608751 - The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology.
Vereecke L, Beyaert R, van Loo G. Vereecke L, et al. Trends Immunol. 2009 Aug;30(8):383-91. doi: 10.1016/j.it.2009.05.007. Epub 2009 Jul 28. Trends Immunol. 2009. PMID: 19643665 Review. - Regulation of NF-κB signaling by the A20 deubiquitinase.
Shembade N, Harhaj EW. Shembade N, et al. Cell Mol Immunol. 2012 Mar;9(2):123-30. doi: 10.1038/cmi.2011.59. Epub 2012 Feb 20. Cell Mol Immunol. 2012. PMID: 22343828 Free PMC article. Review.
Cited by
- Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis.
Culver-Cochran AE, Hassan A, Hueneman K, Choi K, Ma A, VanCauwenbergh B, O'Brien E, Wunderlich M, Perentesis JP, Starczynowski DT. Culver-Cochran AE, et al. Nat Commun. 2024 Oct 24;15(1):9189. doi: 10.1038/s41467-024-53629-z. Nat Commun. 2024. PMID: 39448591 Free PMC article. - Somatic mutations in autoinflammatory and autoimmune disease.
Torreggiani S, Castellan FS, Aksentijevich I, Beck DB. Torreggiani S, et al. Nat Rev Rheumatol. 2024 Nov;20(11):683-698. doi: 10.1038/s41584-024-01168-8. Epub 2024 Oct 11. Nat Rev Rheumatol. 2024. PMID: 39394526 Review. - A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors.
Schultheiß C, Paschold L, Mohebiany AN, Escher M, Kattimani YM, Müller M, Schmidt-Barbo P, Mensa-Vilaró A, Aróstegui JI, Boursier G, de Moreuil C, Hautala T, Willscher E, Jonas H, Chinchuluun N, Grosser B, Märkl B, Klapper W, Oommen PT, Gössling K, Hoffmann K, Tiegs G, Czernilofsky F, Dietrich S, Freeman A, Schwartz DM, Waisman A, Aksentijevich I, Binder M. Schultheiß C, et al. Sci Adv. 2024 Aug 23;10(34):eadl3975. doi: 10.1126/sciadv.adl3975. Epub 2024 Aug 21. Sci Adv. 2024. PMID: 39167656 Free PMC article. - Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.
Mukohara F, Iwata K, Ishino T, Inozume T, Nagasaki J, Ueda Y, Suzawa K, Ueno T, Ikeda H, Kawase K, Saeki Y, Kawashima S, Yamashita K, Kawahara Y, Nakamura Y, Honobe-Tabuchi A, Watanabe H, Dansako H, Kawamura T, Suzuki Y, Honda H, Mano H, Toyooka S, Kawazu M, Togashi Y. Mukohara F, et al. Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2320189121. doi: 10.1073/pnas.2320189121. Epub 2024 Aug 21. Proc Natl Acad Sci U S A. 2024. PMID: 39167601 - The past 25 years in paediatric rheumatology: insights from monogenic diseases.
Ozen S, Aksentijevich I. Ozen S, et al. Nat Rev Rheumatol. 2024 Sep;20(9):585-593. doi: 10.1038/s41584-024-01145-1. Epub 2024 Aug 7. Nat Rev Rheumatol. 2024. PMID: 39112602 Review.
References
- Nat Immunol. 2004 Oct;5(10):1052-60 - PubMed
- Genes Chromosomes Cancer. 2008 Jan;47(1):1-7 - PubMed
- J Exp Med. 1993 Feb 1;177(2):339-49 - PubMed
- Nature. 2004 Aug 5;430(7000):694-9 - PubMed
- Blood. 2002 Feb 15;99(4):1474-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources